Gene therapy for hemoglobinopathies.
Gene therapy cures sickle cell and thalassemia in the short term, though long-term safety monitoring continues.
The review assessed gene-modified hematopoietic stem-cell therapy for hemoglobinopathies. Two commercial products show strong short- and intermediate-term efficacy, while conditioning toxicity, fertility, organ outcomes, and malignancy risk require longer follow-up.
What the study was
- Study design
- Narrative clinical review
- Population
- Patients with sickle cell disease or transfusion-dependent thalassemia
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Seminars in hematology
Why it surfaced
The review addresses transformative treatment for high-unmet-need disorders, but long-term safety evidence remains incomplete
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.